Navigation Links
Simcere Pharmaceutical Group Reports Preliminary Unaudited First Quarter 2013 Results
Date:5/9/2013

4,580Bills receivable

679,630

614,257

98,901Accounts receivable, net

413,481

419,796

67,591Inventories

120,932

97,521

15,702Other current assets

237,248

221,442

35,654Total current assets1,743,3971,776,483286,031Property, plant and equipment, net

853,546

848,367

136,596Land use rights

128,220

127,466

20,523Goodwill and intangible assets, net

519,334

512,119

82,456Investments in and advances to affiliated companies

56,785

41,487

6,680Other non-current assets

71,381

96,304

15,506Total assets3,372,663

3,402,226

547,792LiabilitiesCurrent liabilitiesShort-term borrowings

675,779

735,770

118,466Accounts payable

47,136

35,371

5,695Bills payable

15,000

-

-Other payables and accrued liabilities

471,603

444,518

71,572Total current liabilities1,209,5181,215,659195,733Long-term borrowings

2,000

2,000

322Deferred tax liabilities

56,120

50,072

8,062Other liabilities

32,657

31,657

5,097Total liabilities1,300,2951,299,388209,214Shareholders' equitySimcere shareholders' equity Ordinary shares at par

8,258

8,259

1,330Additional paid-in capital

853,551

863,329

139,004Accumulated other comprehensive loss

(104,147)

(104,211)

(16,779)Retained earnings

1,254,464

1,284,407

206,802Total equity attributable to Simc
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
2. Simcere Pharmaceutical Group to Announce First Quarter 2013 Financial Results on Thursday, May 9, 2013
3. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
4. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
5. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Legal Counsel
6. Simcere Pharmaceutical Group Announces Receipt of "Going Private" Proposal
7. Simcere Pharmaceutical Group Reports Preliminary Unaudited Fourth Quarter And Full Year 2012 Results
8. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013
9. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
11. Simcere Pharmaceutical Group to Announce Third Quarter 2012 Financial Results on Thursday, November 15, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced ... at Emory University, presented long-term follow up data on ... cells in the treatment of amyotrophic lateral sclerosis (ALS ... occurred at the Annual Symposium on ALS of the ... on Friday, and was not open to the public, ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a ... solutions for medical and surgical procedures, among other ... deal with Munich -based Brainlab ... ® Navigation. This agreement applies to the ... cross-disciplinary U.S. sales and all distribution outside the ...
(Date:9/22/2014)... , Sept. 22, 2014  Inovio Pharmaceuticals, Inc. ... has initiated a phase I clinical trial in ... the safety, tolerability, and immunogenicity of INO-3106. This ... causes most aerodigestive cancers. Aerodigestive cancers ... cords, and parts of the esophagus and windpipe. ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... , , DALLAS , February ... and Central Labs events present Advanced,Biomarker Strategies in Oncology Drug Development. ... from February 4-5, 2010 . This,event is FREE for executives ... This two-day program focuses exclusively on the latest developments in,oncology biomarkers. ...
... RESEARCH TRIANGLE PARK, N.C. , Jan. 29 ... the U.S. Food and Drug Administration has approved ... in patients ages 13 years and older with primary generalized ... XR is approved for partial onset seizures ...
Cached Medicine Technology:MarketsandMarkets Partners With IIR USA for Their Event 'Advanced Biomarker Strategies in Oncology Drug Development' 2MarketsandMarkets Partners With IIR USA for Their Event 'Advanced Biomarker Strategies in Oncology Drug Development' 3FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 2FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 3FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 4FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 5FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 6FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 7
(Date:9/22/2014)... (PRWEB) September 22, 2014 The New ... Department of Surgery at the Icahn School of Medicine ... New York Group for Plastic Surgery gives residents of ... to a team of world-renowned plastic surgeons performing innovative ... Andrew Salzberg, MD, who led NYGPS, was named the ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 WHO: ... center and customer service solutions. , WHAT: The ... focused on customer care for the connected consumer. ... continue to offer new challenges and opportunities for ... helping attendees identify best practices, network and learn ...
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... California for a three-day conference to discuss brain-related ... brain injury from concussions and neurodegenerative disorders. ... medical director affiliated with a Silverado memory care ... of dedicated expertise in memory care, hosts the ...
(Date:9/22/2014)... ARBOR, Mich. Many parents whose kids participate in ... concussion education, but that,s not enough to ensure parents ... new University of Michigan C.S. Mott Children,s Hospital National ... half of the 912 parents of middle and high ... concussion education: , , 23% have read a ...
(Date:9/22/2014)... (Sept. 22, 2014) The success of a colonoscopy ... bowel prep often resulting in missed precancerous lesions, according ... Task force on Colorectal Cancer. Additionally, poor bowel cleansing ... procedures. Up to 20 to 25 percent of all ... , "When prescribing bowel preparation for their patients, ...
Breaking Medicine News(10 mins):Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3Health News:Some concussion education more useful than others, parents say 2Health News:Good bowel cleansing is key for high-quality colonoscopy 2Health News:Good bowel cleansing is key for high-quality colonoscopy 3
... Something rotten never smelled so sweet. This is ... Laboratory (CSHL) are telling one another as they discuss a new ... that hydrogen sulfide (H2S) the flammable, highly toxic gas that ... and sewers plays an important role in the regulation of ...
... lifestyle habits relate to the risk of certain cancers (e.g., ... authors estimate the proportion of cancer in the population associated ... find that smoking has, by far, the largest effect on ... the UK attributable to tobacco use. A poor diet ...
... their arms asymmetrically -- one arm swings less than ... easily detected early when drugs and other interventions may ... who used inexpensive accelerometers on the arms of Parkinson,s ... known for some time that people with Parkinson,s disease ...
... York, NY, December 13, 2011JDRF-funded researchers have begun enrolling ... study, to test whether metformina drug commonly used to treat ... cardiovascular complications in people with T1D. The REMOVAL study ... multi-center, international trial that will study 500 patients with T1D ...
... Ph.D., Associate Professor of Surgery at Thomas Jefferson University ... and Related Cancers Center , and Mon-Li Chu, ... Dermatology and Cutaneous Biology , were awarded $200,000 from ... Concept Program for their breakthrough work on a ...
... or a bed has to deal with numerous complications. ... physicians call them. Bony prominences, such as the sacrum, ... can lead to tissue necrosis. Damage can extend into ... The ulcers are entryways for germs, which can trigger ...
Cached Medicine News:Health News:Unexpected signaling role for foul-smelling hydrogen sulfide in cell response to protein misfolding 2Health News:Unexpected signaling role for foul-smelling hydrogen sulfide in cell response to protein misfolding 3Health News:Increased arm swing asymmetry is early sign of Parkinson's disease 2Health News:Increased arm swing asymmetry is early sign of Parkinson's disease 3Health News:JDRF-funded study seeks to reduce cardiovascular risk 2Health News:Thomas Jefferson University receives Science Center's QED Award for pancreatic cancer research 2Health News:Thomas Jefferson University receives Science Center's QED Award for pancreatic cancer research 3Health News:Lying and sitting more comfortably 2
The first book to translate key medical data into clear guidelines capturing the highest treatment standards for heart disease....
DxRxValv contains tables and figures to summarize important clinical data and current professional society recommendations. This handy manual details precise, up-to-date information for diagnosis and...
... Dx/Rx: Coronary Thrombosis ... flowcharts which facilitate transformation ... protocols from static images ... support tools. Details precise, ...
Cardiology Intensive Board Review is geared specifically to candidates taking the Cardiovascular Boards and the Cardiovascular section of the Internal Medicine Boards....
Medicine Products: